Oncology for the Inquisitive Mind

San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, t…

Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lu…

As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired i…

Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatou…

Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a "sandwich sett…

Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to …

Colorectal cancer remains the bread and butter of many an oncologist, but its commonality belies its complexity. In early and advanced disease alike, there remain many permutations, considerations an…

Next up on the ESMO 2023 rollercoaster is an episode that is likely to be the shortest in our series: upper gastrointestinal and hepatobiliary oncology. As always, this remains a very challenging sub…

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall s…

Welcome back to Oncology for the Inquisitive Mind's ongoing coverage of ESMO 2023. In the spirit of a worldwide oncology conference, here we present results from three very exciting trials in the ear…

Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug th…

ESMO 2023 showcased several promising trials in the small-cell lung cancer space. A cancer that continues to send shivers down the spine of budding oncologists for decades. Today, we look at several …

Michael and Josh continue their examination of the crème-de-la-crème of the European Society of Medical Oncology conference of 2023. Today they focus on metastatic breast cancer, with a particular fo…

Another year, another international oncology conference in a beautiful European locale. In 2023, the world's oncology community has descended on the Spanish capital Madrid to discuss the latest and g…

Cisplatin is the mainstay for concurrent chemoradiotherapy in Locally Advanced Head and Neck Cancers. What happens to that significant group of patients who cannot have cisplatin? Michael and Josh fo…

Cancer inherently increases the risk of Deep Vein Thrombosis and Pumlmonary Embolism. This is merely a nuisance for some, while others experience significant morbidity, leading to hemodynamic instabi…

Gynaecological malignancies are a diverse group of terrible malignancies. From ovarian to endometrial to cervical, these cancers are notorious not just for their mortality burden, but the significant…

It is frequently said that it takes a village to treat a patient with cancer. However, beyond the nuts and bolts of medical and allied health treatment, there exists a whole other world of advocacy a…

"I have not failed, I've just found 10,000 ways that won't work!" so said Thomas Edison in describing his journey to the incandescent light bulb. This quote seemed appropraite as Michael and Josh con…

Neuroendocrine Tumours could be described as an impassable obstacle, more complicated the more you research. That's where Michael and Josh come in, and this week, explore Grade 3 metastatic neuroendo…